Effect of β2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment

Seung Hyun Kim, Young Min Ye, Gyu Young Hur, Hyun Young Lee, Young Koo Jee, Seung Ho Lee, John W. Holloway, Hae Sim Park

    Research output: Contribution to journalArticlepeer-review

    12 Citations (Scopus)


    Purpose: Combination treatment of inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) is widely used as a maintenance regimen for the management of asthma. This study evaluated the effect of the β2-adrenergic receptor (ADRB2) polymorphism on lung function and asthma control with regular use of combination treatment of an inhaled ICS plus LABA. Materials and Methods: 43 Korean asthmatics who were symptomatic despite regular ICS use for at least 3 months were enrolled. For a 2-week run-in period, they received ICS (budesonide 800 μg/day) plus terbutaline (5 μg prn). as needed. During the 24-week active treatment period, they received budesonide 160 μg and formoterol 4.5 μg b.i.d. as maintenance and rescue medication. Pulmonary function and quality of life scores were monitored every 8 weeks; morning/evening peak expiratory flow meter (PEFR) was recorded daily. Patients were genotyped for ADRB2 Arg16Gly using single base extension methodology. Results: During the run-in period, there were no significant between-group differences in lung function; after 8 weeks of active treatment, Arg/Arg patients had significantly higher forced expiratory volume in 1 secord (FEV 1) and maximal mid-expiratory flow (MMEF) (p = 0.023 and p = 0.021, respectively), and better asthma control and quality of life after 24 weeks (p = 0.016 and p = 0.028, respectively). During treatment, there was a greater improvement in morning/evening PEFR in Arg/Arg patients. Conclusion: Asthmatic patients with the Arg/Arg genotype at codon 16 of ADRB2 achieve better asthma control with long-term regular use of combined budesonide and formoterol treatment, suggesting that the ADRB2 genotype may dictate choice of treatment strategy.

    Original languageEnglish
    Pages (from-to)182-188
    Number of pages7
    JournalYonsei medical journal
    Issue number2
    Publication statusPublished - 2009


    • Bronchodilating effect
    • Long-acting β2-agonist
    • β2-adrenergic receptor polymorphism

    ASJC Scopus subject areas

    • Medicine(all)


    Dive into the research topics of 'Effect of β2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment'. Together they form a unique fingerprint.

    Cite this